Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

[N-Acetyl-Ser1]-Teriparatide

● Auf Lager

Katalog-Nr.::	VE0025141
CAS-Nr.::	N/A
Summenformel::	C183H293N55O52S2
Molare Masse::	4159.8 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu [N-Acetyl-Ser1]-Teriparatide

Parent drug

Teriparatide

IUPAC-Name

Acetyl-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

Pharmakopöe-Synonyme

N/A

Other Synonyms

N/A

SMILES

O=C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C)=O)CO)=O)C(C)C)=O)CO)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CCC(N)=O)=O)CC(C)C)=O)CCSC)=O)CC1=CNC=N1)=O)CC(N)=O)=O)CC(C)C)=O)=O)CCCCN)=O)CC2=CNC=N2)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)CCSC)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CCC(O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCCN)=O)CC(C)C)=O)CCC(N)=O)=O)CC(O)=O)=O)C(C)C)=O)CC5=CNC=N5)=O)CC(N)=O)=O)CC6=CC=CC=C6)O

InChI

InChI=1S/C183H293N55O52S2/c1-22-97(18)148(238-161(269)115(49-54-143(253)254)214-175(283)134(85-241)234-179(287)147(96(16)17)237-176(284)132(83-239)206-98(19)242)180(288)218-112(46-51-136(188)244)156(264)221-120(66-91(6)7)164(272)215-117(56-63-292-21)159(267)226-125(72-102-80-197-87-204-102)168(276)228-127(74-137(189)245)170(278)219-118(64-89(2)3)149(257)202-82-140(248)207-106(40-28-31-57-184)150(258)225-124(71-101-79-196-86-203-101)167(275)223-122(68-93(10)11)165(273)227-129(76-139(191)247)172(280)233-133(84-240)174(282)216-116(55-62-291-20)158(266)212-113(47-52-141(249)250)154(262)210-110(44-35-61-200-183(194)195)160(268)235-145(94(12)13)177(285)217-114(48-53-142(251)252)157(265)224-123(70-100-78-201-105-39-27-26-38-104(100)105)166(274)222-121(67-92(8)9)162(270)211-109(43-34-60-199-182(192)193)152(260)208-107(41-29-32-58-185)151(259)209-108(42-30-33-59-186)153(261)220-119(65-90(4)5)163(271)213-111(45-50-135(187)243)155(263)230-130(77-144(255)256)173(281)236-146(95(14)15)178(286)231-126(73-103-81-198-88-205-103)169(277)229-128(75-138(190)246)171(279)232-131(181(289)290)69-99-36-24-23-25-37-99/h23-27, 36-39, 78-81, 86-97, 106-134, 145-148, 201, 239-241H, 22, 28-35, 40-77, 82-85, 184-186H2, 1-21H3, (H2, 187, 243)(H2, 188, 244)(H2, 189, 245)(H2, 190, 246)(H2, 191, 247)(H, 196, 203)(H, 197, 204)(H, 198, 205)(H, 202, 257)(H, 206, 242)(H, 207, 248)(H, 208, 260)(H, 209, 259)(H, 210, 262)(H, 211, 270)(H, 212, 266)(H, 213, 271)(H, 214, 283)(H, 215, 272)(H, 216, 282)(H, 217, 285)(H, 218, 288)(H, 219, 278)(H, 220, 261)(H, 221, 264)(H, 222, 274)(H, 223, 275)(H, 224, 265)(H, 225, 258)(H, 226, 267)(H, 227, 273)(H, 228, 276)(H, 229, 277)(H, 230, 263)(H, 231, 286)(H, 232, 279)(H, 233, 280)(H, 234, 287)(H, 235, 268)(H, 236, 281)(H, 237, 284)(H, 238, 269)(H, 249, 250)(H, 251, 252)(H, 253, 254)(H, 255, 256)(H, 289, 290)(H4, 192, 193, 199)(H4, 194, 195, 200)/t97-, 106-, 107-, 108-, 109-, 110-, 111-, 112-, 113-, 114-, 115-, 116-, 117-, 118-, 119-, 120-, 121-, 122-, 123-, 124-, 125-, 126-, 127-, 128-, 129-, 130-, 131-, 132-, 133-, 134-, 145-, 146-, 147-, 148-/m0/s1

Beschreibung

[N-Acetyl-Ser1]-Teriparatide is the N-terminally acetylated peptide impurity of teriparatide arising from modification of the Ser1 residue. The acetyl addition (+42.01 Da) neutralizes the N-terminal amine | alters peptide pI and hydrophobicity | and typically produces a reproducible retention time shift in reversed-phase HPLC. Formation can occur as a process-related or storage-related side reaction via residual acetyl donors or acylation chemistry during synthesis and workup. Analytical identification is achieved by LC-MS and MS/MS peptide mapping to confirm site-specific modification. Control measures include reagent specification | optimized deprotection protocols | scavengers and validated in-process and release assays to ensure impurity stays within specification.